5 Tech Stocks to Buy Immediately
Eric Fry, one of America's top Investment Strategists, provides his latest report 5 Top Stocks for 2022.

You can't afford to miss out on the once in a decade chance to buy after the recent dip in the markets.
Download this hot-off-the-presses research report now. It’s yours FREE.
Jeff Fairman, insider at Vaxcyte
Jeff Fairman Insider Alerts

Get notified the next time Jeff Fairman buys or sells Vaxcyte stock. Enter your email address below to get our daily insider buying and selling report.

Jeff Fairman Insider Information

VP of Vaxcyte
Jeff has over 20 years of experience in the biotech arena having led the research at multiple platform companies that he co-founded resulting in multiple clinical candidates and approved vaccines and immunotherapeutics. Prior to Vaxcyte, Jeff was the founder and Vice President of Research at Juvaris BioTherapeutics, whose immunotherapeutic & vaccine adjuvant platform yielded multiple animal health products launched by its alliance partner Bayer HealthCare, including Zelnate® and Victrio®. While at Juvaris, Jeff was the recipient of major grant funding from multiple sources, including NIH and NCI, supporting substantial pre-clinical programs and multiple clinical studies. He was responsible for research activities resulting in multiple clinical candidates and the approved animal health products. Prior to Juvaris, Jeff was the Director of Pharmacogenomics at Clingenix and Senior Scientist at Valentis. Dr. Fairman has a Ph.D. in Chemistry and his postdoctoral training was in the genetics of leukemia at MD Anderson Cancer Center. Jeff enjoys spending time with his wife and daughter and has put his amateur taekwondo career on hold, for the time being, to be courtside rooting for his daughter’s school and club volleyball teams.

What is Jeff Fairman's net worth?

The estimated net worth of Jeff Fairman is at least $174,431.22 as of August 26th, 2021. Dr. Fairman owns 9,894 shares of Vaxcyte stock worth more than $174,431 as of January 20th. This net worth estimate does not reflect any other assets that Dr. Fairman may own. Learn More.

How old is Jeff Fairman?

Dr. Fairman is currently 57 years old. There are 6 older executives and no younger executives at Vaxcyte. The oldest executive at Vaxcyte is Mr. Paul W. Sauer M.B.A., MBA, Sr. VP of Process Devel. & Manufacturing, who is 59 years old. Learn More.

How do I contact Jeff Fairman?

The corporate mailing address for Dr. Fairman and other Vaxcyte executives is 353 HATCH DRIVE, FOSTER CITY CA, 94404. Vaxcyte can also be reached via phone at 650-837-0111.

Has Jeff Fairman been buying or selling shares of Vaxcyte?

Jeff Fairman has not been actively trading shares of Vaxcyte during the last quarter. Most recently, Jeff Fairman sold 4,750 shares of the business's stock in a transaction on Monday, December 27th. The shares were sold at an average price of $23.60, for a transaction totalling $112,100.00.

Who are Vaxcyte's active insiders?

Vaxcyte's insider roster includes Jeff Fairman (VP), Andrew Guggenhime (CFO), Grant Pickering (CEO), Paul Sauer (SVP), and Jane Wright-Mitchell (General Counsel).

Are insiders buying or selling shares of Vaxcyte?

In the last year, insiders at the sold shares 36 times. They sold a total of 421,648 shares worth more than $10,503,183.57. The most recent insider tranaction occured on December, 29th when SVP Paul Sauer sold 6,000 shares worth more than $150,000.00. Insiders at Vaxcyte own 21.7 % of the company.

Information on this page was last updated on 12/29/2021.

Jeff Fairman Insider Trading History at Vaxcyte

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
12/27/2021Sell4,750$23.60$112,100.00View SEC Filing Icon  
12/16/2021Sell4,619$22.50$103,927.50View SEC Filing Icon  
12/9/2021Sell131$22.50$2,947.50View SEC Filing Icon  
10/26/2021Sell4,750$22.69$107,777.50View SEC Filing Icon  
9/27/2021Sell4,750$26.17$124,307.50View SEC Filing Icon  
8/26/2021Sell4,750$25.38$120,555.009,894View SEC Filing Icon  
7/26/2021Sell4,750$22.70$107,825.009,894View SEC Filing Icon  
6/28/2021Sell4,750$24.37$115,757.509,894View SEC Filing Icon  
6/7/2021Sell9,500$22.50$213,750.00View SEC Filing Icon  
3/26/2021Sell4,750$23.88$113,430.006,158View SEC Filing Icon  
2/26/2021Sell4,750$23.93$113,667.506,158View SEC Filing Icon  
1/26/2021Sell4,750$25.27$120,032.506,158View SEC Filing Icon  
See Full Table

Jeff Fairman Buying and Selling Activity at Vaxcyte

This chart shows Jeff Fairman's buying and selling at Vaxcyte by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Vaxcyte Company Overview

Vaxcyte logo
Vaxcyte, Inc., a preclinical-stage biotechnology vaccine company, develops novel vaccines to prevent or treat infectious diseases worldwide. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine. The company also develops VAX-XP to protect against emerging strains and address antibiotic resistance; VAX-A1, a conjugate vaccine candidate designed to treat Group A Strep; and VAX-PG, a novel protein vaccine candidate targeting Porphyromonas gingivalis. The company was formerly known as SutroVax, Inc. and changed its name to Vaxcyte, Inc. in May 2020. Vaxcyte, Inc. was incorporated in 2013 and is headquartered in Foster City, California.
Read More

Today's Range

Now: $17.63
Low: $17.44
High: $18.75

50 Day Range

MA: $22.41
Low: $17.63
High: $26.45

2 Week Range

Now: $17.63
Low: $15.51
High: $29.29


407,763 shs

Average Volume

459,339 shs

Market Capitalization

$930.60 million

P/E Ratio


Dividend Yield



Apple Could Be Days Away From Shocking The World
The "Black Box" Device Bringing the Age of the Smartphone to an End.
Learn More